Pharmacodynamic effects of seliciclib (R-roscovitine, CYC202) in patients with undifferentiated nasopharyngeal carcinoma (NPC) using a window trial design.

W. Hsieh, B.K. Peh, T. Loh, J.H. Chiao, R. Soo, C.Y. Cui, S.R. Green, Y.F. Lai, Manuel Salto-Tellez, B. Mow, B.C. Goh

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)8983S-8984S
JournalClinical Cancer Research
Publication statusPublished - Nov 2005

Cite this